ARUP Laboratories

Global $46.7B Cancer Biomarkers Market Outlook, 2035: MET Biomarkers Lead the Charge, Driven by Rising Incidence of Lung Cancer and Drug Development - ResearchAndMarkets.com

Retrieved on: 
수요일, 5월 8, 2024
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Foundation Medicine, MSI, Lung cancer, Breast cancer, Blood, AI, MDPI, Skin cancer, Agilent Technologies, Prostate cancer, Biomarker, ALK, Kidney cancer, EGFR, OncoDNA, Cancer, Bladder cancer, Tempus, Son, Non-small-cell lung cancer, Frontiers Media, HER2, Colorectal cancer, Turbine, Thyroid cancer, ARUP Laboratories, Roche, Database, Therapy, Merck, NSCLC, Thermo Fisher Scientific, Nature, Publication, Laboratory, Survival, Insurance, BioMed Central, Nature Portfolio, Incidence, Drug development, Liver cancer, Liquid biopsy, MET, NTRK, CK Life Sciences, Endometrial cancer, Actuate, PD-L1, Patient, Gastrointestinal cancer, Physician, Neoplasm, Head, Medical imaging

Based on the type of cancer, the cancer biomarkers market is segmented into Breast Cancer, Prostate Cancer, Colorectum Cancer, Lung Cancer, Thyroid Cancer, Bladder Cancer, Melanoma, Non-Hodgkins Lymphoma, Endometrial Cancer, Kidney Cancer and Leukemia.

Key Points: 
  • Based on the type of cancer, the cancer biomarkers market is segmented into Breast Cancer, Prostate Cancer, Colorectum Cancer, Lung Cancer, Thyroid Cancer, Bladder Cancer, Melanoma, Non-Hodgkins Lymphoma, Endometrial Cancer, Kidney Cancer and Leukemia.
  • Currently, the market is driven by breast cancer biomarkers and lung cancer biomarkers; however, in the coming future, we anticipate cancer biomarker market for leukemia to grow at a significant pace.
  • The market report features an extensive study of the current market landscape, market size, market forecast and future opportunities for the companies involved in the cancer biomarkers market.
  • It is worth mentioning that Merck is conducting the maximum number of trials in this industry for various cancer indications, including bladder cancer, breast cancer, colorectal cancer, gastrointestinal cancer, gynecological cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, prostate cancer and skin cancer.

ARUP Statement on FDA Final Rule to Regulate Laboratory-Developed Tests as Medical Devices

Retrieved on: 
월요일, 4월 29, 2024
FDA, Congress, Laboratory, ARUP, CLEP, MDA, MD, Doctor of Philosophy, Synovial joint, ARUP Laboratories, Patient, Medicare, Health, Medical device

SALT LAKE CITY, April 29, 2024 /PRNewswire/ -- A final FDA rule regulating laboratory-developed tests (LDTs) as medical devices does not address serious concerns raised by ARUP Laboratories and the clinical laboratory community, and the company's stance on the rule has not changed, CEO Andy Theurer said today.

Key Points: 
  • SALT LAKE CITY, April 29, 2024 /PRNewswire/ -- A final FDA rule regulating laboratory-developed tests (LDTs) as medical devices does not address serious concerns raised by ARUP Laboratories and the clinical laboratory community, and the company's stance on the rule has not changed, CEO Andy Theurer said today.
  • "ARUP is evaluating and reviewing the final rule, including any changes, internally and with our industry partners, to determine next steps," Theurer said.
  • Congress gave the FDA authority to regulate medical devices, but if Congress had intended the FDA to regulate laboratory-developed testing services as medical devices, lawmakers would have included this concept in the text of the Medical Device Amendments of 1976 (MDA), and it did not.
  • He added that he and ARUP Chief Compliance Officer Jonathan Carr will host an educational webinar on the FDA rule.

Executive War College to Address, Clinical Laboratories’ and Genetic Testing Firms’ Perfect Storm, involving FDA’s Proposed LDT Rule, Payers Requiring Z-Codes on Genetic Test Claims, and Revisions to CLIA Regulations

Retrieved on: 
금요일, 4월 19, 2024
FDA, Health Technology, Publishing, Healthcare Reform, Communications, General Health, Medical Devices, Public Policy, Government, Genetics, Clinical Trials, Science, Biotechnology, Other Science, Health, Research, Dark, Storm, Organization, COLA, Leica Biosystems, Laboratory, Food, CDC, Cleveland Clinic, DLS, MD, Clinical Laboratory, Doctor of Philosophy, ISO, Pathology, Artificial intelligence, History, Genetic testing, ARUP Laboratories, CLIA, Marie Cassidy, Medical device, College, Multimedia, French Quarter, Division, IVD, Darkness

One is the Food and Drug Administration’s (FDA) proposed rule https://www.fda.gov/news-events/press-announcements/fda-proposes-rule-ai... to regulate laboratory developed tests (LDTs).

Key Points: 

ARUP Partners With ELLKAY to Bring Connectivity Solutions to Health System Outreach Operations

Retrieved on: 
수요일, 4월 24, 2024
Laboratory, ARUP, Hospital, ASCP, EHR, Health care, Electronic health record, Partnership, Workflow, ARUP Laboratories, Patient safety, Health information management, Patient, MBA, Growth

SALT LAKE CITY, April 24, 2024 /PRNewswire/ -- ARUP Laboratories and healthcare connectivity company ELLKAY have forged a new partnership aimed at helping health systems establish or expand successful laboratory outreach operations.

Key Points: 
  • SALT LAKE CITY, April 24, 2024 /PRNewswire/ -- ARUP Laboratories and healthcare connectivity company ELLKAY have forged a new partnership aimed at helping health systems establish or expand successful laboratory outreach operations.
  • "ELLKAY gives health systems the tools to exchange data securely across various systems, including the EHR, registration, payers, the lab, and more."
  • ARUP Healthcare Advisory Services provides expert consultation to health systems seeking to establish or expand laboratory outreach operations.
  • Healthcare consultations include operations assessments, marketing opportunity analyses, and business planning guidance to empower health systems to grow sustainable, profitable outreach operations.

AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee

Retrieved on: 
목요일, 3월 28, 2024
Novartis, Acute lymphoblastic leukemia, Head, LG, Translational research, Urology, Oncology, Drug discovery, Executive, LG Chem, Lung, Anschutz Medical Campus, Committee, SRL Diagnostics, University, Laboratory, Doctor of Philosophy, RWTH Aachen University, Senior, Radiopharmaceutical, European Medicines Agency, ARUP Laboratories, Therapy, Drug development, Pharmacology, Pharmaceutical industry

BOSTON, March 25, 2024 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”), an LG Chem company, today announced the appointment of Edgar E. Braendle, MD, PhD as AVEO Oncology’s new Chief Medical Officer. Dr. Braendle is a life sciences executive with experience spanning from early drug discovery to the launch of small molecules, biologics, radiopharmaceuticals, gene and cell therapies, and medical device development.

Key Points: 
  • BOSTON, March 25, 2024 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”), an LG Chem company, today announced the appointment of Edgar E. Braendle, MD, PhD as AVEO Oncology’s new Chief Medical Officer.
  • “We are delighted to have Dr. Braendle join the AVEO Oncology team particularly at this important juncture as we seek to become a global top 20 oncology leader,” said Michael P. Bailey, President and Chief Executive Officer of AVEO Oncology, an LG Chem company.
  • Today, AVEO Oncology, an LG Chem company, and LG Chem Life Sciences also announced the formation of its Scientific Advisory Committee (“Committee”).
  • The Scientific Advisory Committee is comprised of several leading cancer experts, including:
    Professor and Deputy Chair for Translational Research, Department of Gastrointestinal Medical Oncology
    University of Colorado Cancer Center, Aurora

Recursion Hosts Second Annual Rare Disease Day Events for Utah’s Rare Disease Community

Retrieved on: 
금요일, 3월 1, 2024
Rare disease, RUN, Intelligence, Drug discovery, Nature, Hope, Entrepreneurship, ARUP Laboratories, University, Organization, Patient, Disease, Diagnosis, Biology, RDAC, RARE, Recursion, Laboratory, Partnership, Pharmaceutical industry

An estimated one in 10 people in the United States have a rare disease.

Key Points: 
  • An estimated one in 10 people in the United States have a rare disease.
  • The event recognized advocates who have been instrumental in building Utah’s rare disease community and have dedicated themselves to support this important work.
  • “There is an urgency for diagnoses, treatment and cures for the rare disease community,” said Gina Zanik, co-founder and executive director of Rare and Undiagnosed Network and Vice Chair of the Utah Rare Disease Advisory Council.
  • Rare disease patients came together at Recursion with the RARE and Undiagnosed Network (RUN), RARE-X , BioHive , ARUP Laboratories , BioUtah , the University of Utah and the Rare Disease Advisory Council (RDAC) for the Rare Disease Day event.

Vast Therapeutics Expands Leadership Team with Appointment of Dr. Paul Bruinenberg as Chief Medical Officer

Retrieved on: 
목요일, 3월 7, 2024
Rochester University, Bronchiectasis, Roche, Cystic fibrosis, MD, NIH, Medical director, Nephrotoxicity, Astellas Pharma, MBA, TB, ARUP Laboratories, University of Utah, University, Therapy, Pathology, TB Alliance, Associate, Patient, Duke University, Diagnosis, Tuberculosis, Pseudomonas aeruginosa, NTM, Publication, IND, Pharmaceutical industry

MORRISVILLE, N.C., March 7, 2024 /PRNewswire/ -- Vast Therapeutics today announced the addition of Paul Bruinenberg, MD, MBA as Chief Medical Officer. Dr. Bruinenberg brings over 30 years of experience as a clinical development executive in respiratory medicine and orphan diseases. This appointment and the recent addition of microbiologist and clinical diagnostics expert Chris Polage, MD, as Medical Director, significantly bolster the company's clinical development expertise in pulmonary infectious diseases and medical microbiology. 

Key Points: 
  • MORRISVILLE, N.C., March 7, 2024 /PRNewswire/ -- Vast Therapeutics today announced the addition of Paul Bruinenberg, MD, MBA as Chief Medical Officer.
  • "Paul's development experience will guide Vast Therapeutics as we successfully transition to a clinical-stage organization," said Nate Stasko, Chief Executive Officer at Vast Therapeutics.
  • "It is an amazing opportunity to join a company with an accepted IND for a novel treatment modality that shows promising efficacy against chronic infections caused by Pseudomonas aeruginosa and non-tuberculosis mycobacteria," commented Paul Bruinenberg, Chief Medical Officer at Vast Therapeutics.
  • Most recently, Dr. Bruinenberg served as the Senior Medical Officer of the TB Alliance leading clinical development against mycobacterial infections.

Lab Community "Extremely Concerned" About Patient Access to Testing If FDA Regulates Lab-Developed Tests

Retrieved on: 
화요일, 3월 5, 2024
Marie Cassidy, Doctor of Philosophy, ARUP, MD, Synovial joint, Physician, FDA, ARUP Laboratories, Culture, 2005 in television, Manuscript, LDT, Feedback, Safety, Health, MedRxiv, Patient, Congress, Laboratory, Public, Medical device

"If labs cannot afford to comply with the proposed regulations, they will have to discontinue essential tests, and that harms patients."

Key Points: 
  • "If labs cannot afford to comply with the proposed regulations, they will have to discontinue essential tests, and that harms patients."
  • To better understand how clinical laboratorians perceive the proposed rule, ARUP Laboratories conducted a survey of the clinical laboratory community.
  • Most respondents identified themselves as lab managers, lab supervisors, lab directors, lab employees, medical directors, pathologists, physicians, clinicians, or PhD scientists.
  • Over a hundred thousand clinical laboratorians dedicate their professional lives to ensuring high-quality testing and patient care every day in the U.S.

Partnership Between ARUP and Medicover Expands Access to Companion Diagnostic in the European Union

Retrieved on: 
수요일, 12월 6, 2023
ARUP Laboratories, Safety, Haemophilia, European Medicines Agency, CDX, Plasma, CE marking, Laboratory, EMA, Patient, Medicine, European, FDA, ARUP, BioMarin Pharmaceutical, MBA, MD, Partnership, Clinical trial, Antibody, Haemophilia A, IVDR, Injury, Health, Sodium, Medical device, Vaccine, Pharmaceutical industry, Medicover Hospitals

SALT LAKE CITY, Dec. 6, 2023 /PRNewswire/ -- A partnership between ARUP Laboratories and Medicover has made a new companion diagnostic, and thereby a new gene therapy, more accessible to patients in the European Union.

Key Points: 
  • SALT LAKE CITY, Dec. 6, 2023 /PRNewswire/ -- A partnership between ARUP Laboratories and Medicover has made a new companion diagnostic, and thereby a new gene therapy, more accessible to patients in the European Union.
  • "Our ultimate goal, in partnership with BioMarin, is to make AAV5 DetectCDx™ available in all markets where ROCTAVIAN will be authorized so that patients have access to this revolutionary treatment."
  • The approval of the AAV5 DetectCDx™ Kit is the result of a close collaboration between ARUP, Medicover, and BioMarin.
  • "Our PharmaDx group exists to support companion diagnostic testing for the development of cutting-edge therapies in diseases with significant unmet clinical need.

ARUP's New Institute for Research and Innovation in Diagnostic and Precision Medicine™ Will Forge the Future of Laboratory Medicine

Retrieved on: 
금요일, 9월 29, 2023
San Francisco, Laboratory, University, Clinical trial, CSO, ARUP Laboratories, University of California, San Francisco, COVID-19, Pathology, Stanford University, Research, Attention, History, SALT, Doctor of Philosophy, Translation, Harvard Medical School, ARUP, HERO, Stanford University School of Medicine, Leukemia, Tron Lightcycle Power Run, Patient, Machine learning, Physician, Lymphoma, Flow cytometry, Artificial intelligence, New institutional economics, Diagnosis, Growth, R, FDA, Medical device, Pharmaceutical industry, Medical imaging, MD

SALT LAKE CITY, Sept. 29, 2023 /PRNewswire/ -- ARUP Laboratories today announced the formation of the new ARUP Institute for Research and Innovation in Diagnostic and Precision Medicine™ (R&I Institute).

Key Points: 
  • SALT LAKE CITY, Sept. 29, 2023 /PRNewswire/ -- ARUP Laboratories today announced the formation of the new ARUP Institute for Research and Innovation in Diagnostic and Precision Medicine™ (R&I Institute).
  • The institute will improve the lives of patients by advancing groundbreaking diagnostic and prognostic technologies and innovative tests.
  • Now, with a broad vision as CSO and president of the Innovation Business Unit, her attention has turned to the R&I Institute.
  • "We've seen the need and the opportunity, and now we're here to fearlessly seek out the future of laboratory medicine."